Raptor Pharmaceuticals, DaVita announce collaboration Raptor Pharmaceutical (RPTP) and DaVita (DVA) announced a collaboration to screen blood samples from patients with end-stage renal disease in an effort to identify patients with unrecognized late-onset nephropathic cystinosis. DCR will supply blood samples with clinical data annotation from DCR's biorepository of over four thousand patients with ESRD. The screening effort will employ high-throughput genetic sequencing of the cystinosin, lysosomal cystine transporter gene, mutations of which result in cystinosis. Results of the collaboration may reveal new insights into the prevalence of missed late-onset cystinosis in this at-risk patient population.
News For RPTP;DVA From The Last 14 Days
Check below for free stories on RPTP;DVA the last two weeks.